News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon®

PDF ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer Screening Blood Test Compared to a Fecal Test Berlin (Germany) and Germantown, MD (U.S.A.), January 11, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the results of the ADMIT study have been published in the peer-reviewed journal Cancer Treatment and Research […]

Read more

Epigenomics AG to participate in investor conferences

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 14, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that Greg Hamilton, Chief Executive Officer, will participate in the following investor conferences: -Canaccord Genuity Medical Technologies & Diagnostics Forum, Thursday November 17, 2016, New York, Westin New York Grand Central, Presentation: 10:00 am […]

Read more

Epigenomics AG Announces 2016 Third Quarter and Nine Months Financial Results and Reports on Operational Highlights

PDF Revenue increased by 83% in Q3 2016 over same period the prior year Full-year 2016 revenue guidance tightened to EUR 3.5m to EUR 5.0m Epigenomics signs exclusive distribution agreement for Epi proColon in South-East Asia Financial position improved by raising EUR 5.0 million in a private placement to UChip Technology Ltd, a subsidiary of […]

Read more

ARUP Laboratories to Offer Epi proColon®, Epigenomics’ Blood-Based Colorectal Cancer Screening Test

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that ARUP Laboratories (Salt Lake City, Utah) is the next major U.S. laboratory to offer Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer screening. “I am excited about the inclusion of our […]

Read more

Epigenomics AG: Journal of the American Medical Association (JAMA) publishes “letter to the editor” that clarifies clinical performance data for Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), October 26, 2016 – The Journal of the American Medical Association (JAMA) published a “letter to the editor” discussing the importance of participation and clarifying clinical performance data for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening. In June 2016, JAMA had published […]

Read more

Congressman Donald M. Payne, Jr. Introduces Bipartisan 2016 Colorectal Cancer Detection Act

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and Germantown, MD (U.S.A.), September 29, 2016 – Congressman Donald M. Payne, Jr. (D-NJ), today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act of 2016” at a panel discussion held in Washington D.C. The […]

Read more
......